Kari Lenita Falck Moore

Author information from the last article

Avdeling for blodsykdommer

Oslo myelomatosesenter

Oslo universitetssykehus

Avdeling for blod- og kreftsykdommer

Stavanger universitetssjukehus

Forfatterbidrag: utforming, datainnsamling, tolking av data, litteratursøk, revisjon av manuset og godkjenning av innsendte manusversjon.

Kari Lenita Falck Moore er ph.d., spesialist i indremedisin og i blodsykdommer og overlege.

Articles by Kari Lenita Falck Moore

High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008–2020

Jakob Nordberg Nørgaard,
Kari Lenita Falck Moore,
Tobias S. Slørdahl,
Anders Vik,
Tor Henrik Anderson Tvedt,
Hedda Berg Monsen,
Fredrik Schjesvold

13.04.2026: High-dose melphalan and autologous haematopoietic stem-cell transplantation (ASCT) has been used to treat multiple myeloma in Norway since the 1990s (1). In this treatment, the patient receives high-dose chemotherapy with melphalan, followed by reinfusion of the patient's previously harvested stem...

Uncommon adverse effect of a common medication

Kari Lenita Falck Moore,
Odd Kildahl-Andersen,
Randi Kildahl-Andersen,
Geir E. Tjønnfjord

22.01.2013: A woman in her fifties had been suffering for many years from iron deficiency anaemia as a result of unexplained heavy urinary iron loss (1). She had been receiving blood transfusions and intravenous iron supplements for 15 years, most recently in the form of large doses of iron (III) carboxymaltose...